Cytokinetics, Inc. (CYTK) Posts Surprise Q4 Profit; Issues Solid Outlook

February 6, 2014 4:08 PM

Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of $0.21, $0.29 better than the analyst estimate of ($0.08). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found